Multivariate analyses showed that erlotinib was a marker of longer PFS ( HR = 0.35 ; P = 0.0003 ) , whereas high BCL2L11 expression was a marker of longer PFS ( HR = 0.49 ; P = 0.0122 ) and overall survival ( HR = 0.53 ; P = 0.0323 ) .